195 related articles for article (PubMed ID: 17443009)
1. Improving the institutional submission and approval process for clinical research protocols in oncology.
Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R
J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009
[No Abstract] [Full Text] [Related]
2. Health care disparity: an overlooked problem in phase I oncology trials.
O'Brien TE
J Clin Oncol; 2007 Jul; 25(21):3182-3. PubMed ID: 17634502
[No Abstract] [Full Text] [Related]
3. Palliative care and the ethics of research: Medicare, hospice, and phase I trials.
Byock I
J Support Oncol; 2003; 1(2):139-41. PubMed ID: 15352657
[No Abstract] [Full Text] [Related]
4. Barriers to clinical trials vary according to the type of trial and the institution.
Govindarajan R; Young JW; Harless CL; Hutchins LF
J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
[No Abstract] [Full Text] [Related]
5. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
6. The role of independent review to insure ethical quality-improvement activities in oncology: a commentary on the national debate regarding the distinction between quality-improvement initiatives and clinical research.
Markman M
Cancer; 2007 Dec; 110(12):2597-600. PubMed ID: 17960605
[No Abstract] [Full Text] [Related]
7. Phase III trials in oncology: setting standards of care?
Seeber S; Braun AH
Nat Clin Pract Oncol; 2005 Sep; 2(9):426-7. PubMed ID: 16264993
[No Abstract] [Full Text] [Related]
8. The ethics of phase 0 oncology trials.
Abdoler E; Taylor H; Wendler D
Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
[TBL] [Abstract][Full Text] [Related]
9. The phase III candidate: can we improve the science of selection?
Bajorin D
J Clin Oncol; 2004 Jan; 22(2):211-3. PubMed ID: 14665614
[No Abstract] [Full Text] [Related]
10. Cost effectiveness, chemotherapy, and the clinician.
Griggs JJ; Sorbero ME
Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
[No Abstract] [Full Text] [Related]
11. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
Fiorino T
J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
[No Abstract] [Full Text] [Related]
12. Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology.
Markman M
Cancer; 2007 Mar; 109(6):1003-6. PubMed ID: 17311306
[No Abstract] [Full Text] [Related]
13. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
14. Clinical trials and tribulations. Spiraling costs threaten gridlock.
Malakoff D
Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
[No Abstract] [Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. Long overdue: phase II studies in older cancer patients: where does the FDA stand?
Balducci L; Tam-McDevitt J; Hauser R; Simon J
J Clin Oncol; 2008 Mar; 26(8):1387-88. PubMed ID: 18323564
[No Abstract] [Full Text] [Related]
17. The importance of practice patterns.
Scott RS
Adm Radiol; 1995 Nov; 14(11):74, 76. PubMed ID: 10154788
[No Abstract] [Full Text] [Related]
18. [Quality management within the competence network of paediatric oncology and haematology].
Creutzig U; Zimmermann M; Hannemann J; Krämer I; Herold R; Henze G
Klin Padiatr; 2003; 215(6):338-40. PubMed ID: 14677099
[TBL] [Abstract][Full Text] [Related]
19. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
20. Cancer clinical trials: the emergence and development of a new style of practice.
Keating P; Cambrosio A
Bull Hist Med; 2007; 81(1):197-223. PubMed ID: 17369668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
